{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:19:32Z","timestamp":1793085572878,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022336","name":"Esperion Therapeutics Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jacc.2024.04.048","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T10:03:22Z","timestamp":1719828202000},"page":"152-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Comparative Cardiovascular Benefits of\u00a0Bempedoic Acid and Statin Drugs"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8175-2121","authenticated-orcid":false,"given":"A. Michael","family":"Lincoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik K.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Sasiela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Libby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun G.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9493","key":"10.1016\/j.jacc.2024.04.048_bib1","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"issue":"9753","key":"10.1016\/j.jacc.2024.04.048_bib2","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.jacc.2024.04.048_bib3","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.jacc.2015.02.020","article-title":"Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2\u00a0\u00d7 2 factorial Mendelian randomization study","volume":"65","author":"Ference","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.jacc.2024.04.048_bib4","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease","volume":"60","author":"Ference","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.jacc.2024.04.048_bib5","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/eurheartj\/eht571","article-title":"Mendelian randomization of blood lipids for coronary heart disease","volume":"36","author":"Holmes","year":"2014","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.jacc.2024.04.048_bib6","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMoa1806747","article-title":"Mendelian randomization study of ACLY and cardiovascular disease","volume":"380","author":"Ference","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.jacc.2024.04.048_bib7","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"27","key":"10.1016\/j.jacc.2024.04.048_bib8","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1093\/eurheartj\/ehx450","article-title":"Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration","volume":"39","author":"Ference","year":"2018","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jacc.2024.04.048_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.jacc.2024.04.048_bib10","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.jacc.2024.04.048_bib11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jacl.2015.03.003","article-title":"Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance","volume":"9","author":"Thompson","year":"2015","journal-title":"J\u00a0Clin Lipidol"},{"issue":"15","key":"10.1016\/j.jacc.2024.04.048_bib12","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.04.048_bib13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ahj.2020.10.060","article-title":"Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance","volume":"235","author":"Nicholls","year":"2021","journal-title":"Am Heart J"},{"issue":"9841","key":"10.1016\/j.jacc.2024.04.048_bib14","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jacc.2024.04.048_bib15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic effects of statins on the cardiovascular system","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.jacc.2024.04.048_bib16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jacl.2023.02.002","article-title":"Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial","volume":"17","author":"Ridker","year":"2023","journal-title":"J\u00a0Clin Lipidol"},{"issue":"2","key":"10.1016\/j.jacc.2024.04.048_bib17","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0021-9150(03)00193-X","article-title":"Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin","volume":"169","author":"Nawawi","year":"2003","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.jacc.2024.04.048_bib18","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/j.1582-4934.2010.01036.x","article-title":"Statins potently reduce the cytokine-mediated IL-6 release in SMC\/MNC cocultures","volume":"15","author":"Loppnow","year":"2011","journal-title":"J\u00a0Cell Mol Med"},{"issue":"6","key":"10.1016\/j.jacc.2024.04.048_bib19","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1161\/01.ATV.0000163840.63685.0c","article-title":"Statins reduce interleukin-6\u2013induced C-reactive protein in human hepatocytes","volume":"25","author":"Arnaud","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10","key":"10.1016\/j.jacc.2024.04.048_bib20","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/ng.3396","article-title":"A\u00a0comprehensive 1000 Genomes\u2013based genome-wide association meta-analysis of coronary artery disease","volume":"47","author":"Nikpay","year":"2015","journal-title":"Nat Genet"},{"issue":"6890","key":"10.1016\/j.jacc.2024.04.048_bib21","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nature00804","article-title":"Subendothelial retention of atherogenic lipoproteins in early atherosclerosis","volume":"417","author":"Sk\u00e5l\u00e9n","year":"2002","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.jacc.2024.04.048_bib22","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1161\/CIRCULATIONAHA.106.676890","article-title":"Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications","volume":"116","author":"Tabas","year":"2007","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.jacc.2024.04.048_bib23","first-page":"2499","article-title":"Lipid-related markers and cardiovascular disease prediction","volume":"307","year":"2012","journal-title":"JAMA"},{"issue":"9602","key":"10.1016\/j.jacc.2024.04.048_bib24","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","article-title":"Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths","volume":"370","author":"Lewington","year":"2007","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.jacc.2024.04.048_bib25","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.jacc.2024.04.048_bib26","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.jacc.2024.04.048_bib27","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/nep.13709","article-title":"Intention to treat and per protocol analysis in clinical trials","volume":"25","author":"Tripepi","year":"2020","journal-title":"Nephrology (Carlton)"},{"issue":"1","key":"10.1016\/j.jacc.2024.04.048_bib28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/jama.286.1.64","article-title":"Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation\/CRP evaluation (PRINCE): a randomized trial and cohort study","volume":"286","author":"Albert","year":"2001","journal-title":"JAMA"},{"issue":"26","key":"10.1016\/j.jacc.2024.04.048_bib29","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJM200106283442601","article-title":"Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events","volume":"344","author":"Ridker","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.jacc.2024.04.048_bib30","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/01.CIR.100.3.230","article-title":"Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators","volume":"100","author":"Ridker","year":"1999","journal-title":"Circulation"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109724072267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109724072267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T15:18:53Z","timestamp":1719847133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109724072267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0735109724072267"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2024.04.048","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Cardiovascular Benefits of\u00a0Bempedoic Acid and Statin Drugs","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2024.04.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}